RPMI 8226 - CCL-155 - ATCC
RPMI 8226 are B lymphocytes isolated in 1966 from the peripheral blood derived from a 61-year-old, male, plasmacytoma patient. RPMI 8226 can be used in immunology and immune system research.
Evaluating the efficacy of multiple myeloma cell lines as models for ...
2020年3月2日 · Notably, some widely used cell lines (RPMI-8226, U-266) scored poorly in our patient similarity ranking (48 and 52 of 66, respectively). Lines cultured with interleukin-6 showed significantly...
The surfaceome of multiple myeloma cells suggests potential ...
2022年7月15日 · RPMI-8226 cells were treated with 50 μM Lenalidomide (Sigma CDS022536), 7.5 nM Bortezomib (Selleck Chemicals, S1013), or 300 nM CB-5083 (gift of Cleave Biosciences).
Bortezomib resistance in multiple myeloma is associated with …
2017年8月29日 · Bortezomib resistance is not solely driven by adaptations of the proteasome. a Cell viability of RPMI-8226 wild type (WT) and bortezomib-resistant (BTZ/7 and BTZ/100) cells after a 48-h treatment with increasing concentrations of bortezomib.
Force-Regulated Calcium Signaling of Lymphoid Cell RPMI 8226 …
2023年3月24日 · Flou-4 AM was used to examine the calcium response under real-time fluorescence microscopy when cells were firmly adhered to a parallel plate flow chamber. The interaction between integrin α4β7 and MAdCAM-1 was found to effectively trigger calcium signaling in firmly adhered RPMI 8226 cells.
Cellosaurus cell line RPMI-8226 (CVCL_0014)
Doubling time: 60 hours (PubMed=25984343); ~60-70 hours (DSMZ=ACC-402); 33.5 hours (NCI-DTP=RPMI-8226). Microsatellite instability: Stable (MSS) (Sanger). Omics: Array-based CGH.
Anti-TACI single and dual-targeting CAR T cells overcome BCMA …
2023年11月18日 · In a subcutaneous model of RPMI-8226, we observed stronger efficacy and survival of animals treated with anti-BCMA–anti-TACI CAR compared to TriPRIL CAR (Supplementary Fig. 6b, c), suggesting...
Teclistamab is an active T cell–redirecting bispecific antibody against ...
2020年9月21日 · In the RPMI 8226 regression model, teclistamab inhibited tumor growth up to day 60, with both the 10 µg and 50 µg doses exhibiting significant tumor reductions compared with PBS control.
Acquired Resistance to Bortezomib in Human RPMI-8226 …
2008年11月16日 · In the present study we investigated whether chronic exposure to BTZ could provoke acquired resistance to BTZ in the human RPMI-8226 MM cell line model and whether a PSMB5 gene mutation would be responsible.
Leibniz Institute | RPMI-8226 - DSMZ
Species: human (Homo sapiens) Cell type: multiple myeloma. Origin: established from the peripheral blood of a 61-year-old man with multiple myeloma (IgG lambda-type) at diagnosis in 1966; described in the literature to produce and secrete …
- 某些结果已被删除